- Home
- RDIB vs SGHT Comparison
RDIB vs SGHT Comparison
Compare RDIB & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDIB
- SGHT
- Stock Information
- Founded
- RDIB 1937
- SGHT 2011
- Country
- RDIB United States
- SGHT United States
- Employees
- RDIB N/A
- SGHT N/A
- Industry
- RDIB Movies/Entertainment
- SGHT Medical Specialities
- Sector
- RDIB Consumer Discretionary
- SGHT Health Care
- Exchange
- RDIB Nasdaq
- SGHT Nasdaq
- Market Cap
- RDIB 140.2M
- SGHT 140.1M
- IPO Year
- RDIB N/A
- SGHT 2021
- Fundamental
- Price
- RDIB $7.02
- SGHT $2.32
- Analyst Decision
- RDIB
- SGHT Buy
- Analyst Count
- RDIB 0
- SGHT 7
- Target Price
- RDIB N/A
- SGHT $3.83
- AVG Volume (30 Days)
- RDIB 12.4K
- SGHT 274.7K
- Earning Date
- RDIB 05-14-2025
- SGHT 03-05-2025
- Dividend Yield
- RDIB N/A
- SGHT N/A
- EPS Growth
- RDIB N/A
- SGHT N/A
- EPS
- RDIB N/A
- SGHT N/A
- Revenue
- RDIB $210,527,000.00
- SGHT $79,866,000.00
- Revenue This Year
- RDIB N/A
- SGHT $3.09
- Revenue Next Year
- RDIB $18.29
- SGHT $13.61
- P/E Ratio
- RDIB N/A
- SGHT N/A
- Revenue Growth
- RDIB N/A
- SGHT N/A
- 52 Week Low
- RDIB $5.78
- SGHT $2.17
- 52 Week High
- RDIB $21.34
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- RDIB 46.06
- SGHT 38.48
- Support Level
- RDIB $6.06
- SGHT $2.64
- Resistance Level
- RDIB $7.39
- SGHT $3.13
- Average True Range (ATR)
- RDIB 1.00
- SGHT 0.22
- MACD
- RDIB -0.18
- SGHT -0.04
- Stochastic Oscillator
- RDIB 15.38
- SGHT 5.62
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.